← ANALYST RATINGS · TIPRANKS
Lantheus (LNTH): analyst forecast and price target
Analyst consensus
Hold0 Buy9 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $104, the highest $109, the lowest $102. The average is +4.8% from the last price of $99.70.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $108 → $110+1.9% | Buy | +10.3% | Upgrade | 15.10.26on TipRanks 02:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $112 → $113+0.9% | Buy | +13.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $109 → $110+0.9% | Hold | +10.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $105 → $108+2.9% | Hold | +8.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $111 → $118+6.3% | Buy | +18.4% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $115 → $109−5.2% | Hold | +9.3% | Downgrade | 13.10.26on TipRanks 07:15 | −0.1%next day +1.1% | ↗ |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $116 → $113−2.6% | Buy | +13.3% | Reiterated | 02.10.26on TipRanks 18:07 | — | |
| Yuan Zhi★★★★★★★★★★#1180 · hits 41% · avg +20.7% | B. Riley Securities | $129 → $105−18.3% | Hold | +5.7% | Downgrade | 18.08.26on TipRanks Aug 17 13:08 | +0.4%next day 0.0% · 5 days +1.1% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | — | Hold | — | Reiterated | 14.08.26on TipRanks 10:30 | +0.2%next day +0.4% · 5 days +0.4% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Hold | — | Reiterated | 08.08.26on TipRanks Aug 6 15:50 | −0.3%next day −0.7% · 5 days −1.3% | ↗ |
| Lawrence Solow★★★★★★★★★★#3322 · hits 60% · avg +21.1% | CJS Securities | — | Hold | — | Downgrade | 04.08.26on TipRanks 08:42 | −1.9%next day +0.6% · 5 days −0.3% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $125 → $102−18.0% | Hold | +2.8% | Downgrade | 04.08.26on TipRanks Aug 3 14:06 | +0.1%next day −1.9% · 5 days −2.2% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $110 → $102−6.8% | Hold | +2.8% | Downgrade | 03.08.26on TipRanks 11:55 | +0.1%next day −1.9% · 5 days −2.2% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $102 | Hold | +2.8% | Downgrade | 03.08.26on TipRanks 11:25 | +0.1%next day −1.9% · 5 days −2.2% | ↗ |
| Kemp Dolliver★★★★★★★★★★#7059 · hits 33% · avg +1.3% | Brookline Capital Markets | $105 | Hold | +5.3% | Downgrade | 28.07.26on TipRanks 18:08 | −1.0%next day −0.7% · 5 days −4.0% | ↗ |
| Unknown Analyst | Baptista Research | $105 | Sell | +5.2% | Initiated | 16.06.26on TipRanks Jun 20 00:05 | +0.9%next day −0.5% · 5 days +1.9% | ↗ |
| David Turkaly★★★★★★★★★★#11791 · hits 40% · avg −4.0% | Citizens JMP | $85.00 → $115+35.3% | Buy | +15.3% | Reiterated | 08.05.26on TipRanks 06:05 | +1.4%next day +0.9% · 5 days +0.7% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $82.00 → $94.00+14.6% | Hold | −5.7% | Reiterated | 07.05.26on TipRanks 18:35 | +1.4%next day +0.9% · 5 days +0.7% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $110 | Buy | +10.3% | Reiterated | 18.03.26on TipRanks Mar 17 15:30 | +2.2%next day +1.1% · 5 days −5.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Lantheus
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $105 at a price of $99.53 (+6.0%); now: $104 at $99.70 (+4.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 17 | 14 | 18 | 10 | 6 | 0 |
| Hold | 2 | 2 | 3 | 10 | 10 | 10 |
| Sell | 0 | 1 | 1 | 1 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.26 (from $0.98 to $1.44). Last quarter: $1.55.
Sales
Next quarter’s sales estimate — $361M (from $345M to $395M). Last quarter: $388M.
Best top-analyst consensus in the sector · Healthcare
About Lantheus
- CEO: Mary Anne Heino
- Employees: 1,193
- 201 Burlington Road, Bedford, MA, 01730, US
- www.lantheus.com
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They fost
Data from the stock’s TipRanks forecast page, read 33 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗